Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
EunYoung Ze, Eun Kyung Baek, Jong Jin Lee, Han Wook Chung, Dae Geon Ahn, Hwan Jun Cho, Jae Cheol Kwon, Hyung Joon Kim, HyunWoong Lee
Clin Mol Hepatol. 2014;20(3):267-273. Published online 2014 Sep 25 DOI: https://doi.org/10.3350/cmh.2014.20.3.267
Citations to this article as recorded by 
Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient
Quan Zhang, Junhao Chen, Mingjie Pan, Jingli Liu, Tingting Liu, Yi-Hua Zhou
Virus Research.2018; 255: 165. CrossRef
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Scott Fung, Peter Kwan, Milotka Fabri, Andrzej Horban, Mijomir Pelemis, Hie-Won Hann, Selim Gurel, Florin A. Caruntu, John F. Flaherty, Benedetta Massetto, Kyungpil Kim, Kathryn M. Kitrinos, G. Mani Subramanian, John G. McHutchison, Leland J. Yee, Magdy E
Journal of Hepatology.2017; 66(1): 11. CrossRef
The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine
Hyun Woong Lee, Sung Hee Lee, Min Goo Lee, Sang Hoon Ahn, Hye Young Chang, Kwang‐Hyub Han
Journal of Medical Virology.2016; 88(5): 820. CrossRef
Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis
Hui-Lian Wang, Xi Lu, Xudong Yang, Nan Xu
Gastroenterology Research and Practice.2016; 2016: 1. CrossRef
Adefovir dipivoxil/lamivudine/entecavir
Reactions Weekly.2015; 1568(1): 20. CrossRef